Working… Menu
Trial record 20 of 22 for:    "Hemosiderosis" | "Iron Chelating Agents"

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01090323
Recruitment Status : Completed
First Posted : March 19, 2010
Results First Posted : January 20, 2011
Last Update Posted : June 6, 2011
Information provided by:

Brief Summary:
The safety, tolerability, effects on liver iron concentration and pharmacokinetics of ICL670 is studied in sickle cell disease patients with transfusional hemosiderosis.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: ICL670 Phase 2

Detailed Description:
The treatment period started once the patient completed the core study and signed informed consent. It is continued for up to 4 years. Safety parameters were assessed every 4 weeks. Eye and Ear examinations were performed on a yearly basis. To further investigate the extent of iron overload, serum ferritin, iron, and transferrin were monitored every four weeks. The Program Safety Board monitored the safety of ICL670 during the study to evaluate and categorize any serious case reported in association with ICL670.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 185 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A One Year Open Label, Non-comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration (LIC) of Repeated Doses of 5-30mg/kg/Day ICL670 Relative to Deferoxamine (DFO) in Sickle Cell Disease (SCD) Patients With Transfusional Hemosideresis (THS) [Amendment 3: Extension Prolonged to 4-years]
Study Start Date : July 2004
Actual Primary Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Iron

Arm Intervention/treatment
Experimental: ICL670 Drug: ICL670
Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.

Primary Outcome Measures :
  1. Number of Participants With Adverse Events After Start of ICL670 [ Time Frame: 0 - 60 months ]
    Safety as assessed by the number of participants with adverse event or death after the start of ICL670.

Secondary Outcome Measures :
  1. Change in Serum Ferritin From Start of ICL670 to End of Study [ Time Frame: 0 - 60 months ]
    The main efficacy variable was change in serum ferritin in response to therapy with ICL670. Due to variability of serum ferritin, end of study was considered as the mean of at most the last 3 available observations after the start of ICL670.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients were included who met the following criteria:

  • Completion of the core [Study 0109]
  • Serum ferritin greater than or equal to 500 µg/L
  • Ability to comply with all study-related procedures, medications, and evaluations
  • Sexually active post-menarche female patients must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months.
  • Written informed consent and assent by the patient and or their parents or legal guardian.

Additional inclusion criteria for pediatric patients The definition of the term 'pediatric' for enrollment and study conduct was in accordance with local law. Parents or the legal guardians were fully informed by the investigator as to the requirements of the study. The pediatric patients themselves were informed according to their capabilities in a language and terms that they were able to understand. Written informed consent was obtained from their legal guardian on the patient's behalf in accordance with national legislation. If capable, all patients had to also personally sign their written informed consent.

Exclusion Criteria:

Patients who met the following criteria were to be excluded:

  • History of non-compliance to medical regimens and patients who are considered potentially unreliable and/or not cooperative
  • Serum creatinine above the age-appropriate upper limit of normal within one week prior to entry
  • Patients with ALT ≥ 500 U/L within one week prior to entry
  • Evidence of chelation-related cataracts or hearing loss within 4 weeks prior to baseline
  • Pregnancy (as indicated by serum β-HCG pregnancy test for all female patients with the potential to become pregnant) and patients who are breastfeeding
  • Patients treated with systemic investigational drug within 4 weeks prior to or with topical investigational drug within 7 days prior to the baseline visit

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01090323

  Show 39 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT01090323     History of Changes
Obsolete Identifiers: NCT00171197
Other Study ID Numbers: CICL670A0109E1
EudraCT no. 2004-000597-31 ( Registry Identifier: EudraCT )
First Posted: March 19, 2010    Key Record Dates
Results First Posted: January 20, 2011
Last Update Posted: June 6, 2011
Last Verified: May 2011
Keywords provided by Novartis:
Iron chelators
Sickle Cell Disease
Transfusional Hemosiderosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Iron Chelating Agents
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action